Factor XI inhibitors for the prevention of cardiovascular disease: A new therapeutic approach on the horizon?

IF 6.9 2区 医学 Q1 HEMATOLOGY Blood Reviews Pub Date : 2023-11-01 DOI:10.1016/j.blre.2023.101119
D. Santagata , M.P. Donadini , W. Ageno
{"title":"Factor XI inhibitors for the prevention of cardiovascular disease: A new therapeutic approach on the horizon?","authors":"D. Santagata ,&nbsp;M.P. Donadini ,&nbsp;W. Ageno","doi":"10.1016/j.blre.2023.101119","DOIUrl":null,"url":null,"abstract":"<div><p>Anticoagulant drugs<span><span> that are currently used to prevent and/or treat thrombosis have some limitations that hinder their ability to meet specific clinical requirements. While these drugs<span> effectively reduce the rates of thrombotic events, they simultaneously increase the risk of bleeding. Moreover, their risk-to-benefit balance is problematic in some patients, such as those with severe chronic kidney disease or those at high bleeding risk. A novel </span></span>anticoagulation<span> method, FXI<span> inhibition has emerged as a promising alternative. It demonstrates a strong rationale for the prevention and treatment<span> of venous thromboembolism and the potential fulfillment of unmet clinical needs in the cardiovascular field. A number of FXI inhibitors are currently undergoing clinical investigation. The objective of this review is to provide an overview of early results of research on FXI inhibitors in the cardiovascular setting, offering valuable insights into their potential role in shaping the future of anticoagulation.</span></span></span></span></p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X23000802","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Anticoagulant drugs that are currently used to prevent and/or treat thrombosis have some limitations that hinder their ability to meet specific clinical requirements. While these drugs effectively reduce the rates of thrombotic events, they simultaneously increase the risk of bleeding. Moreover, their risk-to-benefit balance is problematic in some patients, such as those with severe chronic kidney disease or those at high bleeding risk. A novel anticoagulation method, FXI inhibition has emerged as a promising alternative. It demonstrates a strong rationale for the prevention and treatment of venous thromboembolism and the potential fulfillment of unmet clinical needs in the cardiovascular field. A number of FXI inhibitors are currently undergoing clinical investigation. The objective of this review is to provide an overview of early results of research on FXI inhibitors in the cardiovascular setting, offering valuable insights into their potential role in shaping the future of anticoagulation.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
目前用于预防和/或治疗血栓形成的抗凝药物存在一些局限性,阻碍了它们满足特定临床要求的能力。虽然这些药物有效地降低了血栓形成事件的发生率,但同时也增加了出血的风险。此外,它们的风险-收益平衡在某些患者中是有问题的,例如那些患有严重慢性肾脏疾病或出血风险高的患者。作为一种新的抗凝方法,FXI抑制已成为一种很有前途的替代方法。它为预防和治疗静脉血栓栓塞提供了强有力的理论依据,并有可能满足心血管领域未满足的临床需求。许多FXI抑制剂目前正在进行临床研究。本综述的目的是概述FXI抑制剂在心血管疾病中的早期研究结果,为其在未来抗凝治疗中的潜在作用提供有价值的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Blood Reviews
Blood Reviews 医学-血液学
CiteScore
13.80
自引率
1.40%
发文量
78
期刊介绍: Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.
期刊最新文献
From MGUS to multiple myeloma: Unraveling the unknown of precursor states. Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies. Corrigendum to "Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?"[BLOOD REVIEWS, 9 August 2024, https://doi.org/10.1016/j.blre.2024.101226]. Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1